Showing results (21-30 of 584) with videos related to
Sort By:
Pageof 59
Cancers|January 11, 2022
Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort ExperienceTina Lamy, Bastien Cabarrou, David Planchard, et al.Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic valueFrancesco Facchinetti, Maria Virginia Bluthgen, Gabrielle Tergemina-Clain, et al.Cancer Research and Treatment|November 28, 2024
The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat?Mariona Riudavets, David PlanchardExpert Opinion on Drug Safety|January 4, 2021
Safety of current immune checkpoint inhibitors in non-small cell lung cancerPamela Abdayem, David PlanchardLung Cancer (Amsterdam, Netherlands)|December 22, 2011
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancerBenjamin Besse, David Planchard, Anne-Sophie Veillard, et al.Expert Review of Respiratory Medicine|June 30, 2018
Durvalumab for the treatment of non-small cell lung cancerLaura Mezquita, David PlanchardFuture Oncology (London, England)|February 20, 2016
Treatment modalities for advanced ALK-rearranged non-small-cell lung cancerIvana Sullivan, David PlanchardExpert Opinion on Pharmacotherapy|December 21, 2022
An update on lorlatinib: a novel first line treatment for <i>ALK</i>-positive advanced lung cancerMariona Riudavets, David PlanchardFrontiers in Medicine|February 3, 2017
Next-Generation <i>EGFR</i> Tyrosine Kinase Inhibitors for Treating <i>EGFR</i>-Mutant Lung Cancer beyond First LineIvana Sullivan, David PlanchardEuropean Respiratory Review : an Official Journal of the European Respiratory Society|July 22, 2021
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancerPamela Abdayem, David PlanchardPageof 59